Api m 10 has recently been established as novel major allergen that is recognized by more than 60% of honeybee venom (HBV) allergic patients. Previous studies suggest Api m 10 protein heterogeneity which may have implications for diagnosis and immunotherapy of HBV allergy. In the present study, RT-PCR revealed the expression of at least nine additional Api m 10 transcript isoforms by the venom glands. Two distinct mechanisms are responsible for the generation of these isoforms: while the previously known variant 2 is produced by an alternative splicing event, novel identified isoforms are intragenic chimeric transcripts. To the best of our knowledge, this is the first report of the identification of chimeric transcripts generated by the honeybee. By a retrospective proteomic analysis we found evidence for the presence of several of these isoforms in the venom proteome. Additionally, we analyzed IgE reactivity to different isoforms by protein array technology using sera from HBV allergic patients, which revealed that IgE recognition of Api m 10 is both isoform- and patient-specific. While it was previously demonstrated that the majority of HBV allergic patients display IgE reactivity to variant 2, our study also shows that some patients lacking IgE antibodies for variant 2 display IgE reactivity to two of the novel identified Api m 10 variants, i.e. variants 3 and 4.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2014.09.018DOI Listing

Publication Analysis

Top Keywords

hbv allergic
12
allergic patients
12
ige reactivity
12
ige recognition
8
protein array
8
array technology
8
isoforms venom
8
novel identified
8
chimeric transcripts
8
display ige
8

Similar Publications

venom allergy (HVA) is an IgE-mediated hypersensitivity reaction caused by species stings (honeybee, vespid, or ant). The only effective treatment is venom immunotherapy (VIT). Our study aimed to evaluate whether humoral and cellular biomarkers measured before, during, and after honeybee VIT are associated with the success of VIT, which was assessed by the response to a sting challenge one year after finishing VIT.

View Article and Find Full Text PDF

Comparative Assessment of the Allergenicity of Hyaluronidases from (Pol d 2), (Ves v 2), and Venom (Api m 2).

Toxins (Basel)

November 2024

Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine and Health & Helmholtz Munich, German Research Center for Environmental Health, 85764 Munich, Germany.

Article Synopsis
  • * Key allergens evaluated include hyaluronidases from honey bee (Api m 2), European paper wasp (Pol d 2), and yellow jackets (Ves v 2.0101 and Ves v 2.0201), with sensitization rates among patients varying significantly.
  • * Results show that individuals primarily sensitized to Api m 2 have minimal cross-reactivity with other venoms, while those sensitized to other allergens may react to Api m 2, emphasizing the importance of identifying the primary allergen for effective
View Article and Find Full Text PDF

Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom.

Asian Pac J Allergy Immunol

May 2024

Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.

Background: The basophil activation test (BAT) has high sensitivity and specificity for diagnosing Hymenoptera venom allergy and is useful for predicting the clinical sensitivity of bee venom-allergic patients after venom immunotherapy. Patients sensitized to Hymenoptera venom are at risk for systemic reactions (SRs) to subsequent stings. Therefore, a tool that can predict the occurrence of SRs and the severity of Hymenoptera stings is needed.

View Article and Find Full Text PDF
Article Synopsis
  • Ixekizumab is a monoclonal antibody used to treat moderate-to-severe plaque psoriasis, showing positive results in terms of effectiveness and tolerance, but there's a lack of safety data specific to Chinese patients.
  • A real-world observational study followed 663 patients in China for adverse events while they received ixekizumab treatment over 12 weeks, evaluating various safety parameters.
  • The study found that about 33.8% of patients reported at least one adverse event related to the treatment, with injection site reactions, infections, and allergic reactions being the most common, and noted that female patients experienced a higher proportion of adverse events compared to males.
View Article and Find Full Text PDF

The safety and efficacy of hemoglobin vesicles (HbVs) as artificial oxygen carriers encapsulating a purified and concentrated Hb solution in liposomes have been studied extensively. The HbV surface, modified with PEG by incorporating a PEG-conjugated phospholipid, is beneficial for storage and biocompatibility. However, it might be possible that interaction of PEG and the pre-existing anti-PEG antibody in the bloodstream causes acute adverse reaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!